Gene-Disorder Association · Article
Gene
KMT2A Lysine Methyltransferase 2A
×
First reported
1993
Supporting publications
14
Manually curated Approved treatment annotated
Association Review
In brief The association between KMT2A (Lysine Methyltransferase 2A) and Leukemia, Acute Myeloid is a manually-curated gene–disease association, supported by 2 contributing sources, 1 of them expert-curated.
Sources
2
Clinical variants
0
Symptoms
5
Compounds
7
Trials
818 of 3,820 via KMT2A compounds
Publications
14
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Leukemia, Acute Myeloid
The disorder 27 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features 1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics 7 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 3,820 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
14 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 17 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access